Top
Main
 
All Outcomes
 
RCT vs. Obs.
 
Feedback
Home
c19early.org COVID-19 treatment researchCurcuminCurcumin (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta
Home Adoption Other Treatments
@CovidAnalysis
Loading...
Analgesics⏵
Antiandrogens⏵
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle⏵
Melatonin
Metformin
Minerals⏵
Molnupiravir
Monoclonals⏵
Naso/orophar..⏵
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins⏵
More⏵

Supplementary Data — Curcumin for COVID-19: real-time meta analysis of 27 studies

@CovidAnalysis, November 2024, Version 43V43
Post
Share
PDF
Studies
Feedback
https://c19early.org/tmeta.html
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Saber-Moghaddam 94% 0.06 [0.00-0.93] progression 0/21 8/20 Improvement, RR [CI] Treatment Control Saber-Moghaddam 38% 0.62 [0.39-0.96] no recov. 11/21 17/20 Saber-Moghaddam 45% 0.55 [0.39-0.79] hosp. time 21 (n) 20 (n) Aldwihi 31% 0.69 [0.43-1.04] hosp. 30/144 207/594 Pawar (DB RCT) 82% 0.18 [0.04-0.79] death 2/70 11/70 OT​1​ Pawar (DB RCT) 60% 0.40 [0.09-1.75] death 2/15 5/15 OT​1​ Pawar (DB RCT) 91% 0.09 [0.01-1.56] death 0/25 5/25 OT​1​ Pawar (DB RCT) 67% 0.33 [0.01-7.87] death 0/30 1/30 OT​1​ Ahmadi (DB RCT) 86% 0.14 [0.01-2.65] hosp. 0/30 3/30 Ahmadi (DB RCT) 21% 0.79 [0.48-1.31] recov. time 30 (n) 30 (n) Sankhe (RCT) 89% 0.11 [0.01-2.03] death 0/87 4/87 CT​2​ Sankhe (RCT) 75% 0.25 [0.03-2.19] ventilation 1/87 4/87 CT​2​ Sankhe (RCT) 46% 0.54 [0.35-0.76] no recov. 29/87 60/87 CT​2​ Sankhe (RCT) 10% 0.90 [0.71-1.15] hosp. time 87 (n) 87 (n) CT​2​ Majeed (DB RCT) 66% 0.34 [0.01-8.09] ventilation 0/45 1/47 CT​2​ Majeed (DB RCT) 80% 0.20 [0.01-4.13] hosp. 0/45 2/47 CT​2​ Majeed (DB RCT) 43% 0.57 [0.39-0.84] no recov. 45 (n) 47 (n) CT​2​ Majeed (DB RCT) 25% 0.75 [0.56-1.01] no recov. 26/45 36/47 CT​2​ Majeed (DB RCT) 6% 0.94 [0.80-1.10] viral time 45 (n) 47 (n) CT​2​ Khan (RCT) 33% 0.67 [0.37-1.19] no recov. 10/25 15/25 CT​2​ Khan (RCT) 39% 0.61 [0.43-0.87] no recov. 25 (n) 25 (n) CT​2​ Khan (RCT) 50% 0.50 [0.30-0.84] viral+ 10/25 20/25 CT​2​ Askari (DB RCT) 26% 0.74 [0.43-1.25] no recov. 13 (n) 13 (n) Askari (DB RCT) -125% 2.25 [0.30-16.6] no recov. 3/8 1/6 Askari (DB RCT) -433% 5.33 [0.30-93.3] no recov. 2/6 0/7 Askari (DB RCT) 73% 0.27 [0.08-0.95] no recov. 2/12 8/13 Askari (DB RCT) 40% 0.60 [0.20-1.77] no recov. 3/10 7/14 Askari (DB RCT) 38% 0.62 [0.21-1.79] no recov. 4/13 4/8 Askari (DB RCT) -71% 1.71 [0.20-14.5] no recov. 2/7 1/6 Askari (DB RCT) 12% 0.88 [0.07-11.5] no recov. 1/8 1/7 Askari (DB RCT) 0% 1.00 [0.25-4.07] no recov. 3/13 3/13 Chitre (DB RCT) 11% 0.89 [0.79-0.99] recov. time 89 (n) 86 (n) CT​2​ Chitre (DB RCT) 11% 0.89 [0.80-0.99] no recov. 70/89 76/86 CT​2​ Chitre (DB RCT) 20% 0.80 [0.64-1.00] no recov. 89 (n) 86 (n) CT​2​ Chitre (DB RCT) 20% 0.80 [0.62-1.04] no recov. 89 (n) 86 (n) CT​2​ Chitre (DB RCT) 14% 0.86 [0.70-1.05] no recov. 89 (n) 86 (n) CT​2​ Chitre (DB RCT) 15% 0.85 [0.67-1.06] no recov. 89 (n) 86 (n) CT​2​ Chitre (DB RCT) 8% 0.92 [0.75-1.12] no recov. 89 (n) 86 (n) CT​2​ Chitre (DB RCT) 17% 0.83 [0.66-1.06] no recov. 89 (n) 86 (n) CT​2​ Chitre (DB RCT) 17% 0.83 [0.66-1.05] no recov. 89 (n) 86 (n) CT​2​ Chitre (DB RCT) 18% 0.82 [0.65-1.03] no recov. 89 (n) 86 (n) CT​2​ Chitre (DB RCT) 25% 0.75 [0.54-1.04] no recov. 89 (n) 86 (n) CT​2​ Chitre (DB RCT) 18% 0.82 [0.66-1.01] no recov. 89 (n) 86 (n) CT​2​ Chitre (DB RCT) 17% 0.83 [0.69-1.01] no recov. 89 (n) 86 (n) CT​2​ Chitre (DB RCT) 17% 0.83 [0.65-1.06] no recov. 89 (n) 86 (n) CT​2​ Din Ujjan (RCT) 29% 0.71 [0.50-1.03] no recov. 15/25 21/25 CT​2​ Din Ujjan (RCT) 71% 0.29 [0.14-0.59] no recov. 6/25 21/25 CT​2​ Din Ujjan (RCT) 77% 0.23 [0.07-0.71] no recov. 3/25 13/25 CT​2​ Din Ujjan (RCT) 86% 0.14 [0.01-2.63] no recov. 0/25 3/25 CT​2​ Din Ujjan (RCT) 91% 0.09 [0.01-1.56] viral+ 0/25 5/25 CT​2​ Din Ujjan (RCT) 74% 0.26 [0.12-0.59] viral+ 5/25 19/25 CT​2​ Kishimoto (DB RCT) 47% 0.53 [0.10-2.90] progression 2/71 4/67 Valizadeh (DB RCT) 50% 0.50 [0.18-1.40] death 4/20 8/20 Tahmasebi (DB RCT) 83% 0.17 [0.02-1.32] death 1/40 6/40 Tahmasebi (DB RCT) 67% 0.33 [0.01-7.72] death 0/20 1/20 Tahmasebi (DB RCT) 80% 0.20 [0.03-1.56] death 1/20 5/20 Hassania.. (DB RCT) -46% 1.46 [0.01-329] SpO2 imp. 20 (n) 20 (n) Asadirad (RCT) 26% 0.74 [0.26-2.12] death 5/27 6/24 Asadirad (RCT) 50% 0.50 [0.14-1.82] progression 3/30 6/30 Asadirad (RCT) 45% 0.55 [0.27-1.09] no recov. 8/27 13/24 Asadirad (RCT) 29% 0.71 [0.22-2.35] no recov. 4/27 5/24 Asadirad (RCT) 41% 0.59 [0.25-1.42] no recov. 6/27 9/24 Asadirad (RCT) 37% 0.63 [0.23-1.74] no recov. 5/27 7/24 Asadirad (RCT) 20% 0.80 [0.58-1.10] no recov. 18/27 20/24 Kartika 41% 0.59 [0.35-1.00] hosp. time 139 (n) 107 (n) Hartono (RCT) 53% 0.47 [0.32-0.68] viral+ 14/30 30/30 CT​2​ Hartono (RCT) 75% 0.25 [0.09-0.66] viral+ 4/30 16/30 CT​2​ Hartono (RCT) 67% 0.33 [0.01-7.87] viral+ 0/30 1/30 CT​2​ Phyto-V Thomas (DB RCT) 44% 0.56 [0.34-0.91] improv. 74 (n) 73 (n) LONG COVID CT​2​ Phyto-V Thomas (DB RCT) 82% 0.18 [0.07-0.47] improv. 74 (n) 73 (n) LONG COVID CT​2​ Phyto-V Thomas (DB RCT) 64% 0.36 [0.16-0.84] improv. 74 (n) 73 (n) LONG COVID CT​2​ Sankhe (SB RCT) 86% 0.14 [0.01-2.71] death 0/60 3/60 CT​2​ Sankhe (SB RCT) 86% 0.14 [0.01-2.71] ventilation 0/60 3/60 CT​2​ Sankhe (SB RCT) 67% 0.33 [0.04-3.11] ICU 1/60 3/60 CT​2​ Sankhe (SB RCT) 10% 0.90 [0.71-1.15] hosp. time 45 (n) 45 (n) CT​2​ Sankhe (SB RCT) 17% 0.83 [0.63-1.10] hosp. time 15 (n) 15 (n) CT​2​ Sankhe (SB RCT) 32% 0.68 [0.54-0.86] recov. time 45 (n) 45 (n) CT​2​ Sankhe (SB RCT) 36% 0.64 [0.49-0.83] recov. time 45 (n) 45 (n) CT​2​ Sankhe (SB RCT) 4% 0.96 [0.75-1.23] recov. time 15 (n) 15 (n) CT​2​ Sankhe (SB RCT) -5% 1.05 [0.99-1.11] recov. time 15 (n) 15 (n) CT​2​ Sankhe (SB RCT) 44% 0.56 [0.38-0.81] viral load 44 (n) 43 (n) CT​2​ Hellou (DB RCT) 77% 0.23 [0.06-0.95] NEWS2 33 (n) 17 (n) CT​2​ Hellou (DB RCT) 92% 0.08 [0.01-0.55] oxygen 0/33 4/17 CT​2​ Hellou (DB RCT) 70% 0.30 [0.05-1.67] oxygen time 33 (n) 17 (n) CT​2​ Hellou (DB RCT) 13% 0.87 [0.07-10.6] hosp. time 33 (n) 17 (n) CT​2​ Hellou (DB RCT) 10% 0.90 [0.47-1.71] viral+ 14/33 8/17 CT​2​ Abbaspour-A.. (RCT) 71% 0.29 [0.06-1.26] death 2/30 7/30 Abbaspour-A.. (RCT) 86% 0.14 [0.02-0.89] no recov. 1/28 6/23 Abbaspour-A.. (RCT) 90% 0.10 [0.01-0.86] no recov. 0/28 4/23 Abbaspour-A.. (RCT) 38% 0.62 [0.32-1.20] no recov. 9/28 12/23 Abbaspour-A.. (RCT) 59% 0.41 [0.12-1.46] no recov. 3/28 6/23 Abbaspour-A.. (RCT) 82% 0.18 [0.01-3.65] no recov. 0/28 2/23 Sadeghiz.. (DB RCT) 92% 0.08 [0.01-0.68] progression 0/21 6/21 Sadeghiz.. (DB RCT) 25% 0.75 [0.62-0.93] hosp. time 21 (n) 21 (n) Sadeghiz.. (DB RCT) 68% 0.33 [0.21-0.49] no recov. 21 (n) 21 (n) Sadeghiz.. (DB RCT) 67% 0.33 [0.04-2.95] no recov. 1/21 3/21 Sadeghiz.. (DB RCT) 80% 0.20 [0.03-1.57] no recov. 1/21 5/21 Sadeghiz.. (DB RCT) 86% 0.14 [0.02-0.96] no recov. 1/21 7/21 Sadeghiz.. (DB RCT) 80% 0.20 [0.01-3.93] no recov. 0/21 2/21 Sadeghiz.. (DB RCT) 75% 0.25 [0.03-2.05] no recov. 1/21 4/21 Sadeghiz.. (DB RCT) 75% 0.25 [0.03-2.05] no recov. 1/21 4/21 Sadeghiz.. (DB RCT) 67% 0.33 [0.01-7.74] no recov. 0/21 1/21 Sadeghiz.. (DB RCT) 50% 0.50 [0.05-5.10] no recov. 1/21 2/21 Sadeghiz.. (DB RCT) 67% 0.33 [0.01-7.74] no recov. 0/21 1/21 Gérain (RCT) 67% 0.33 [0.01-7.70] death 0/25 1/24 CT​2​ Gérain (RCT) 91% 0.09 [0.01-0.71] death/ICU 0/25 5/24 CT​2​ Gérain (RCT) 89% 0.11 [0.01-1.92] ventilation 0/25 4/24 CT​2​ Gérain (RCT) 89% 0.11 [0.01-1.92] ICU 0/25 4/24 CT​2​ Gérain (RCT) 73% 0.27 [0.06-1.19] no disch. 2/25 7/24 CT​2​ Gérain (RCT) 59% 0.41 [0.19-0.89] no disch. 6/25 14/24 CT​2​ Gérain (RCT) 38% 0.62 [0.44-0.88] hosp. time 25 (n) 24 (n) CT​2​ Gérain (RCT) 50% 0.50 [0.26-0.97] no recov. 22 (n) 24 (n) CT​2​ Ahmadi (DB RCT) 58% 0.42 [0.17-1.01] oxygen 5/29 16/39 Ahmadi (DB RCT) 67% 0.33 [0.11-0.96] no recov. 29 (n) 39 (n) Ahmadi (DB RCT) 50% 0.50 [0.15-1.74] no recov. 3/29 8/39 Ahmadi (DB RCT) -34% 1.34 [0.09-20.6] no recov. 1/29 1/39 Ahmadi (DB RCT) 58% 0.42 [0.17-1.01] no recov. 5/29 16/39 Ahmadi (DB RCT) 78% 0.22 [0.01-4.47] no recov. 0/29 2/39 Ahmadi (DB RCT) 64% 0.36 [0.18-0.72] no recov. 7/29 26/39 Ahmadi (DB RCT) 91% 0.09 [0.01-0.84] no recov. 0/29 6/39 Ahmadi (DB RCT) -9% 1.09 [0.71-1.66] no recov. 17/29 21/39 Ahmadi (DB RCT) 10% 0.90 [0.42-1.91] no recov. 8/29 12/39 Ahmadi (DB RCT) 10% 0.90 [0.16-5.02] no recov. 2/29 3/39 Ahmadi (DB RCT) 64% 0.36 [0.02-8.64] no recov. 0/29 1/39 Ahmadi (DB RCT) -234% 3.34 [0.14-79.3] no recov. 1/29 0/39 Bejan 59% 0.41 [0.17-1.00] hosp. 148 (n) 9,600 (n) Shehab 42% 0.58 [0.14-2.32] severe case 2/32 24/221 Nimer 31% 0.69 [0.45-1.04] hosp. 29/329 179/1,819 Nimer 13% 0.87 [0.61-1.24] severe case 40/329 211/1,819 Curcumin COVID-19 outcomes c19early.org November 2024 ​1​ OT: comparison with other treatment​2​ CT: study uses combined treatment Favors curcumin Favors control
Figure S1. All outcomes.
Loading..
Figure S2. Comparison of results for RCTs versus observational studies. For COVID-19 treatments, there is no significant difference between the results of RCTs and observational studies. Observational studies do not systematically over or underestimate efficacy. For high-cost treatments, there is a non-significant trend towards RCTs showing greater efficacy.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0